Prevalence of immunoglobulin G and M to SARS-CoV-2 and other human coronaviruses in The Democratic Republic of Congo, Sierra Leone, and Uganda: A longitudinal study.
Cross-reactivity
Human coronaviruses
Hybrid immunity
SARS-CoV-2
Seroprevalence
Journal
International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases
ISSN: 1878-3511
Titre abrégé: Int J Infect Dis
Pays: Canada
ID NLM: 9610933
Informations de publication
Date de publication:
Jun 2023
Jun 2023
Historique:
received:
03
01
2023
revised:
13
03
2023
accepted:
24
03
2023
medline:
5
5
2023
pubmed:
1
4
2023
entrez:
31
3
2023
Statut:
ppublish
Résumé
We assessed the prevalence of immunoglobulin G (IgG) and IgM against four endemic human coronaviruses and two SARS-CoV-2 antigens among vaccinated and unvaccinated staff at health care centers in Uganda, Sierra Leone, and the Democratic Republic of Congo. The government health facility staff who had patient contact in Goma (Democratic Republic of Congo), Kambia District (Sierra Leone), and Masaka District (Uganda) were enrolled. Questionnaires and blood samples were collected at three time points over 4 months. Blood samples were analyzed with the Luminex MAGPIX Among unvaccinated participants, the prevalence of IgG/IgM antibodies against SARS-CoV-2 receptor-binding domain or nucleocapsid protein at enrollment was 70% in Goma (138 of 196), 89% in Kambia (112 of 126), and 89% in Masaka (190 of 213). The IgG responses against endemic human coronaviruses at baseline were not associated with SARS-CoV-2 sero-acquisition during follow-up. Among the vaccinated participants, those who had evidence of SARS-CoV-2 IgG/IgM at baseline tended to have higher IgG responses to vaccination than those who were SARS-CoV-2 seronegative at baseline, controlling for the time of sample collection since vaccination. The high levels of natural immunity and hybrid immunity should be incorporated into both vaccination policies and prediction models of the impact of subsequent waves of infection in these settings.
Identifiants
pubmed: 37001799
pii: S1201-9712(23)00128-5
doi: 10.1016/j.ijid.2023.03.049
pmc: PMC10060023
pii:
doi:
Substances chimiques
Immunoglobulin G
0
Immunoglobulin M
0
Antibodies, Viral
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
183-192Subventions
Organisme : Medical Research Council
ID : MC_UU_00027/5
Pays : United Kingdom
Organisme : Medical Research Council
ID : MC_UU_00033/1
Pays : United Kingdom
Organisme : Medical Research Council
ID : MR/K019708/1
Pays : United Kingdom
Informations de copyright
Copyright © 2023 The Author(s). Published by Elsevier Ltd.. All rights reserved.
Déclaration de conflit d'intérêts
Declaration of competing interest The authors have no competing interests to declare.
Références
Emerg Microbes Infect. 2021 Dec;10(1):664-676
pubmed: 33734013
Nat Commun. 2021 Aug 6;12(1):4740
pubmed: 34362897
Pediatr Infect Dis J. 2005 Nov;24(11 Suppl):S223-7, discussion S226
pubmed: 16378050
Int J Infect Dis. 2020 Jul;96:517-518
pubmed: 32464272
N Engl J Med. 2022 Jul 7;387(1):21-34
pubmed: 35704396
Vaccines (Basel). 2022 Jun 20;10(6):
pubmed: 35746588
Nat Commun. 2020 Sep 17;11(1):4704
pubmed: 32943637
Clin Infect Dis. 2022 Dec 19;75(12):2243-2246
pubmed: 35686300
J Infect Dis. 2021 Oct 28;224(8):1305-1315
pubmed: 34161567
J Infect Dis. 2022 Aug 26;226(3):474-484
pubmed: 35091739
Science. 2020 Dec 11;370(6522):1339-1343
pubmed: 33159009
J Clin Invest. 2021 Jan 4;131(1):
pubmed: 32997649
Int J Infect Dis. 2023 Feb;127:11-16
pubmed: 36476349
J Mol Med (Berl). 2021 Jan;99(1):93-106
pubmed: 33269412
Open Forum Infect Dis. 2020 Oct 18;7(11):ofaa443
pubmed: 33204751
Wellcome Open Res. 2019 Feb 8;4:26
pubmed: 32518839